Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1982 1
1983 1
1985 1
1987 1
1988 4
1989 3
1990 3
1991 6
1992 6
1993 4
1994 7
1995 3
1996 9
1997 6
1998 5
1999 4
2000 11
2001 3
2002 4
2003 7
2004 11
2005 6
2006 4
2007 8
2008 5
2009 3
2010 5
2011 15
2012 8
2013 11
2014 13
2015 13
2016 14
2017 17
2018 12
2019 11
2020 21
2021 17
2022 14
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Results by year

Filters applied: . Clear all
Page 1
Management of Pigmented Villonodular Synovitis (PVNS): an Orthopedic Surgeon's Perspective.
Bernthal NM, Ishmael CR, Burke ZDC. Bernthal NM, et al. Curr Oncol Rep. 2020 Jun 4;22(6):63. doi: 10.1007/s11912-020-00926-7. Curr Oncol Rep. 2020. PMID: 32494892 Review.
PURPOSE OF REVIEW: Pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumor (TGCT) encompasses a wide spectrum of disease and is divided into localized and diffuse variants. ...
PURPOSE OF REVIEW: Pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumor (TGCT) encompasses a …
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.
Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Rüttinger D. Cannarile MA, et al. J Immunother Cancer. 2017 Jul 18;5(1):53. doi: 10.1186/s40425-017-0257-y. J Immunother Cancer. 2017. PMID: 28716061 Free PMC article. Review.
The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells. ...The specificity of these agents and their potent blocking activity has been substantiated by impressive …
The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in thera …
Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts.
Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hardes J, Hartmann W, Healey J, Italiano A, Jones RL, Kawai A, Leithner A, Loong H, Mascard E, Morosi C, Otten N, Palmerini E, Patel SR, Reichardt P, Rubin B, Rutkowski P, Sangalli C, Schuster K, Seddon BM, Shkodra M, Staals EL, Tap W, van de Rijn M, van Langevelde K, Vanhoenacker FMM, Wagner A, Wiltink L, Stern S, Van de Sande VM, Bauer S. Stacchiotti S, et al. Cancer Treat Rev. 2023 Jan;112:102491. doi: 10.1016/j.ctrv.2022.102491. Epub 2022 Dec 6. Cancer Treat Rev. 2023. PMID: 36502615 Free article. Review.
Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive, mesenchymal tumor arising from the joints, bursa and tendon sheaths. ...
Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive, mesenchymal tumor arising from the joints, …
CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.
Wen J, Wang S, Guo R, Liu D. Wen J, et al. Eur J Med Chem. 2023 Jan 5;245(Pt 1):114884. doi: 10.1016/j.ejmech.2022.114884. Epub 2022 Oct 29. Eur J Med Chem. 2023. PMID: 36335744 Review.
Activation of CSF1R by endogenous cytokine ligation to the ectodomain triggers the autophosphorylation of the intracellular tyrosine kinase domain, and thereafter, activation of several downstream pro-survival kinase cascades, including PI3K, ERK1/2, and JNK. The immunological ro …
Activation of CSF1R by endogenous cytokine ligation to the ectodomain triggers the autophosphorylation of the intracellular tyrosine kinase …
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
Roskoski R Jr. Roskoski R Jr. Pharmacol Res. 2020 Feb;152:104609. doi: 10.1016/j.phrs.2019.104609. Epub 2019 Dec 17. Pharmacol Res. 2020. PMID: 31862477 Review.
Entrectinib binds to TRKA/B/C and ROS1 and is prescribed for the treatment of solid tumors with NTRK fusion proteins and for ROS1-postive non-small cell lung cancers. Erdafitinib inhibits fibroblast growth factor receptors 1-4 and is used in the treatment of urothelial bla …
Entrectinib binds to TRKA/B/C and ROS1 and is prescribed for the treatment of solid tumors with NTRK fusion proteins and for ROS1-postive no …
Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
Alsayadi YMMA, Chawla PA. Alsayadi YMMA, et al. Anticancer Agents Med Chem. 2021;21(12):1510-1519. doi: 10.2174/1871520620999201102123555. Anticancer Agents Med Chem. 2021. PMID: 33143617 Review.
BACKGROUND: Tenosynovial giant cell tumor refers to a group of rarely occurring tumors that are formed in the joints, which are characterized by pain, swelling, and limitation of movement of the joint. Surgery is the main treatment strategy, but the …
BACKGROUND: Tenosynovial giant cell tumor refers to a group of rarely occurring tumors that are formed in the jo …
Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives.
Staals EL, Ferrari S, Donati DM, Palmerini E. Staals EL, et al. Eur J Cancer. 2016 Aug;63:34-40. doi: 10.1016/j.ejca.2016.04.022. Epub 2016 Jun 5. Eur J Cancer. 2016. PMID: 27267143 Review.
At present, the optimal treatment strategy in patients with diffuse-type tenosynovial giant cell tumour (D-TGCT) is unclear. The purpose of this review was to describe current treatment options, and to highlight recent developments in the knowledge of the mol …
At present, the optimal treatment strategy in patients with diffuse-type tenosynovial giant cell tumour (D-TGCT) is unc …
Treatment updates on tenosynovial giant cell tumor.
Palmerini E, Staals EL. Palmerini E, et al. Curr Opin Oncol. 2022 Jul 1;34(4):322-327. doi: 10.1097/CCO.0000000000000853. Curr Opin Oncol. 2022. PMID: 35837703 Review.
PURPOSE OF REVIEW: Diffuse-type tenosynovial giant cell tumor (dt-TGCT) is a benign clonal neoplastic proliferation arising from the synovium. ...RECENT FINDINGS: TGCT cells overexpress colony-stimulating factor 1 (CSF1), resulting in recruitment of CS …
PURPOSE OF REVIEW: Diffuse-type tenosynovial giant cell tumor (dt-TGCT) is a benign clonal neoplastic proliferat …
Optimal Treatment for Tenosynovial Giant Cell Tumor of the Hand.
Kitagawa Y, Takai S. Kitagawa Y, et al. J Nippon Med Sch. 2020 Sep 9;87(4):184-190. doi: 10.1272/jnms.JNMS.2020_87-408. Epub 2020 Apr 30. J Nippon Med Sch. 2020. PMID: 32350187 Free article. Review.
This review examines the following aspects of tenosynovial giant cell tumors (TSGCTs): the use of multiple names, the complex relationship between tumor growth pattern and location, the high rate of postoperative recurrence, local invasiveness, use of …
This review examines the following aspects of tenosynovial giant cell tumors (TSGCTs): the use of multiple names, the c …
Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.
Ravi V, Wang WL, Lewis VO. Ravi V, et al. Curr Opin Oncol. 2011 Jul;23(4):361-6. doi: 10.1097/CCO.0b013e328347e1e3. Curr Opin Oncol. 2011. PMID: 21577109 Review.
PURPOSE OF REVIEW: To review recent developments in the molecular pathogenesis of tenosynovial giant cell tumor (TGCT) or pigmented villonodular synovitis (PVNS) and its therapeutic implications. ...These cells overexpress CSF1, resulting in recruitmen …
PURPOSE OF REVIEW: To review recent developments in the molecular pathogenesis of tenosynovial giant cell tumor …
278 results